The Winship Cancer Institute (Winship) accords highest priority to the conduct of high-impact clinical research developed by its member investigators as an extremely high priority. CCSG Protocol-Specific Research support will provide available resources of the Winship Clinical Trials Office (CTO) and the Phase I Clinical Trials Unit (CTU) to support institutional clinical research studies, for investigator-initiated phase I and II studies. Winship investigators have successfully completed and reported on phase I studies utilizing clinical research infrastructure support from the CTO that includes the acquisition of critical clinical samples in the specialized Phase I CTU. Dedicated clinical research staff members who acquire and process clinical samples for pharmacokinetic, pharmacodynamic, and biomarker sampling can be made available with this support. To achieve the goals of supporting early phase, investigator-initiated clinical research by Winship investigators, the following specific two objectives will be pursued: 1. To identify, initiate, and complete accrual to phase 0, phase I, and phase II institutional clinical research studies which have been authored or co-authored by Winship investigators. 2. To acquire, process, and analyze correlative laboratory samples which advance the scientific goals of the Winship research programs. Success in the completion of scientifically rigorous institutional clinical trials with novel anti-cancer agents will lead to consortium and cooperative group trials that will validate the efficacy of promising new therapies.

Public Health Relevance

; The protocol specific research support facilitates the conduct of high-quality early phased clinical trials at Winship. This avenue also encourages inclusion of translational research as an integral component of such clinical trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Emory University
United States
Zip Code
Danish, Hasan; Ferris, Matthew J; Balagamwala, Ehsan et al. (2018) Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma. Melanoma Res 28:120-125
Barwick, Benjamin G; Scharer, Christopher D; Martinez, Ryan J et al. (2018) B cell activation and plasma cell differentiation are inhibited by de novo DNA methylation. Nat Commun 9:1900
Liu, Fakeng; Liu, Yuan; Liu, Xiuju et al. (2018) Inhibition of IGF1R enhances 2-deoxyglucose in the treatment of non-small cell lung cancer. Lung Cancer 123:36-43
Kennedy, E M; Powell, D R; Li, Z et al. (2018) Galactic Cosmic Radiation Induces Persistent Epigenome Alterations Relevant to Human Lung Cancer. Sci Rep 8:6709
Xiao, Canhua; Beitler, Jonathan J; Higgins, Kristin A et al. (2018) Differential regulation of NF-kB and IRF target genes as they relate to fatigue in patients with head and neck cancer. Brain Behav Immun 74:291-295
Cassidy, Richard J; Zhang, Xinyan; Switchenko, Jeffrey M et al. (2018) Health care disparities among octogenarians and nonagenarians with stage III lung cancer. Cancer 124:775-784
Jhaveri, Jaymin; Chowdhary, Mudit; Zhang, Xinyan et al. (2018) Does size matter? Investigating the optimal planning target volume margin for postoperative stereotactic radiosurgery to resected brain metastases. J Neurosurg :1-7
Jhaveri, Jaymin; Rayfield, Lael; Liu, Yuan et al. (2018) Impact of intensity modulated radiation therapy on survival in anal cancer. J Gastrointest Oncol 9:618-630
Bilen, Mehmet Asim; Dutcher, Giselle Marie Almeida; Liu, Yuan et al. (2018) Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab. Clin Genitourin Cancer 16:e563-e575
Chowdhary, Mudit; Switchenko, Jeffrey M; Press, Robert H et al. (2018) Post-treatment neutrophil-to-lymphocyte ratio predicts for overall survival in brain metastases treated with stereotactic radiosurgery. J Neurooncol 139:689-697

Showing the most recent 10 out of 331 publications